# reload+after+2024-01-23 09:31:44.631265
address1§1 Controls Drive
city§Shelton
state§CT
zip§06484
country§United States
phone§203 937 6137
fax§203 859 5095
website§https://www.nanoviricides.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.
fullTimeEmployees§7
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Anil R. Diwan Ph.D.', 'age': 64, 'title': 'Executive Chairman, President, CEO & Secretary', 'yearBorn': 1959, 'fiscalYear': 2023, 'totalPay': 400000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Meeta R. Vyas B.S., M.B.A., SB, MBA', 'age': 64, 'title': 'Chief Financial Officer', 'yearBorn': 1959, 'fiscalYear': 2023, 'totalPay': 129600, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Randall W. Barton Ph.D.', 'age': 76, 'title': 'Chief Scientific Officer & Chief Regulatory Officer', 'yearBorn': 1947, 'fiscalYear': 2023, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1703980800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.833
currency§USD
dateShortInterest§1702598400
forwardEps§-0.68
exchange§ASE
quoteType§EQUITY
shortName§NanoViricides, Inc.
longName§NanoViricides, Inc.
firstTradeDateEpochUtc§1130333400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§9f404998-ae7c-3809-9925-75444d9a2872
gmtOffSetMilliseconds§-18000000
recommendationMean§2.0
recommendationKey§buy
quickRatio§7.35
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
